Rare target quantification in liquid biopsy
 

dPCR-liquid-biopsy_v2

Liquid biopsies are used to identify and track genetic mutations that cause cancer, enabling researchers to detect cancer early, measure therapeutic response, quantify residual tumor burden, and monitor emerging resistance to potential therapies. Liquid biopsies utilize cell-free DNA (cfDNA) that is derived from cells, both normal and cancerous, that have undergone apoptosis or necrosis and released their DNA contents into their environment (1). The component of cfDNA that is released from cancer cells is more commonly referred to as circulating tumor DNA, or ctDNA.

Detecting ctDNA for liquid biopsy applications is challenging because the molecules bearing the cancer mutations are only a small fraction of the total circulating  cfDNA collected in the sample. Digital PCR (dPCR) is an established method for the fast and reliable identification of genetic mutations. Accurate quantification of single nucleotide polymorphisms that occur in low abundance amongst wild type background DNA requires an appropriate liquid biopsy assay with outstanding sensitivity and specificty. Applied Biosystems Absolute Q Liquid Biopsy dPCR assays are a precise, cost-effective, and rapid method for monitoring response and resistance to treatment by testing for relevant cancer-driver and therapy-resistant mutations.


Absolute Q Liquid Biopsy dPCR assays
 

Absolute Q Liquid Biopsy dPCR assays enable reproducible, specific detection of known somatic mutations. Each predesigned assay has been validated using controls to detect down to 0.1% variant allele frequency in genes relevant for cancer research.

Absolute Q Liquid Biopsy dPCR assays are:

  • Simple—preformulated and verified assay in a single tube, enabling you to immediately start your research
  • Fast—minimal hands-on time; results in 90 minutes when used with the QuantStudio Absolute Q Digital PCR System
  • Highly Sensitive—detect down to 0.1% variant allele frequency
  • Robust—analyze your data with confidence using verified assays backed by a performance guarantee*
     

We stand behind every predesigned Absolute Q dPCR Assay that you buy from us

We guarantee the performance of all of our predesigned Absolute Q assays for dPCR experiments. Our application‑specific portfolio of assays enables you to obtain the highest quality and performance available. These assays are designed and verified using up-to-date annotations and gold-standard Applied Biosystems TaqMan chemistry.

If an Absolute Q Digital PCR Assay does not perform according to conformance documentation, we will replace it at no cost or credit your account.*

Learn more about the Absolute Q dPCR Assay guarantee ›

LowMAF_Data

Figure 1. Quantification of cancer mutations using Absolute Q Liquid Biopsy Digital PCR assays on as QuantStudio Absolute Q Digital PCR System.


Custom designed assays
 

Can’t find the assay you need? Contact us and our experts can help design a digital PCR assay formulated for success based on your target sequence of interest. Or submit the primer/probe sequences of your own design.

Contact us


Complementary master mix

 

Absolute Q DNA Digital PCR Master Mix (5X) is optimized for use with the QuantStudio Absolute Q Digital PCR System and Absolute Q digital PCR assays in a simple workflow with minimal processing steps.  The 5X formulation enables analysis of higher sample volume and delivers accurate quantification of DNA targets without using a standard curve.

Key product features:

  • Fast time-to-results—five minutes of hands-on time and results in ~90 minutes
  • High sensitivity—detect down to 0.1% mutant allele frequency
  • Optimized for multiplexing—detect up to four targets in a single reaction
PipetteImage


Ordering information
 

Absolute Q Liquid Biopsy assays

GeneAmino Acid MutationCDS MutationCOSM IDSKUQty 

BRAF

p.V600K

c.1798_1799delinsAA

473

A52769

p.V600E

c.1799T>A

476

A52743

EGFR

p.L747_A750delinsP

c.2239_2248delinsC

12382

A52777

p.E746_S752delinsV

c.2237_2255delinsT

12384

A52787

p.L747_P753delinsQ

c.2239_2258delinsCA

12387

A52795

p.E746_T751del

c.2236_2253del

12728

A52796

p.L861Q

c.2582T>A

6213

A52762

p.E746_A750del

c.2235_2249del

6223

A52756

p.L858R

c.2573T>G

6224

A52747

p.E746_A750del

c.2236_2250del

6225

A52770

p.G719S

c.2155G>A

6252

A52765

p.G719C

c.2155G>T

6253

A52797

p.L747_S752del

c.2239_2256del

6255

A52780

IDH1

p.R132C

c.394C>T

28747

A52772

JAK2

p.V617F

c.1849G>T

12600

A52746

KIT

p.D816V

c.2447A>T

1314

A52757

KRAS

p.A146V

c.437C>T

19900

A52781

p.G12C

c.34G>T

516

A52750

p.G12S

c.34G>A

517

A52760

p.G12V

c.35G>T

520

A52753

p.G12D

c.35G>A

521

A52745

p.G13C

c.37G>T

527

A52782

NPM1

p.W288Cfs*12

c.860_863dup

17559

A52751

NRAS

p.G12D

c.35G>A

564

A52766

p.Q61K

c.181C>A

580

A52771

PIK3CA

p.H1047R

c.3140 A>G

775

A52749

p.H1047L

c.3140 A>T

776

A52761

TP53

p.R273H

c.818G>A

10660

A52767

p.R248Q

c.743G>A

10662

A52768

p.R273L

c.818G>T

10779

A52779


Absolute Q DNA Digital PCR Master Mix


References
 

  1. Chu D, Park BH (2017) Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Arch 471(2):147–154.

 *Terms and conditions apply. For complete details of the guarantee, go to thermofisher.com/absoluteqassayguarantee

Style Sheet for Global Design System